Caroline J Savage

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
    Amine Benchikh
    Hopital Bichat Claude Bernard, Paris, France
    BMC Cancer 10:635. 2010
  2. pmc Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 19:1201-7. 2010
  3. pmc A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:3232-9. 2010
  4. pmc Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 60:205-10. 2011
  5. pmc Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:907-12. 2010
  6. pmc Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
    Eur Urol 56:753-60. 2009
  7. pmc A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 20:255-61. 2011
  8. pmc Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men
    Robert J Klein
    Program in Cancer Biology and Genetics, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 61:471-7. 2012
  9. pmc Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 128:1697-702. 2011
  10. pmc Prognostic significance of lymphovascular invasion in radical prostatectomy specimens
    David S Yee
    Urology Service, Department of Surgery, Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 108:502-7. 2011

Detail Information

Publications24

  1. pmc A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
    Amine Benchikh
    Hopital Bichat Claude Bernard, Paris, France
    BMC Cancer 10:635. 2010
    ..Here we investigate the properties of our panel in men subject to clinical work-up before biopsy...
  2. pmc Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 19:1201-7. 2010
    ..We sought to describe empirically the distribution of lead times between an elevated prostate-specific antigen (PSA) and subsequent prostate cancer diagnosis...
  3. pmc A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:3232-9. 2010
    ..Although this model accurately predicts the result of biopsy in unscreened men, its properties for men with a history of PSA screening have not been fully characterized...
  4. pmc Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 60:205-10. 2011
    ..Oncologic outcomes in men with radiation-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP) are poorly defined...
  5. pmc Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:907-12. 2010
    ..We determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy...
  6. pmc Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
    Eur Urol 56:753-60. 2009
    ..It has been suggested that changes in prostate-specific antigen (PSA) over time (ie, PSA velocity [PSAV]) aid prostate cancer detection. Some guidelines do incorporate PSAV cut points as an indication for biopsy...
  7. pmc A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 20:255-61. 2011
    ..The clinical significance of biopsy-detectable cancers in men classified as low-risk by this panel remains unclear...
  8. pmc Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men
    Robert J Klein
    Program in Cancer Biology and Genetics, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 61:471-7. 2012
    ..Although case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear...
  9. pmc Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 128:1697-702. 2011
    ..Although our findings have no direct clinical implications, studies investigating biological variables as predictors of outcome after curative resection of cancer should consider the impact of surgeon-specific factors...
  10. pmc Prognostic significance of lymphovascular invasion in radical prostatectomy specimens
    David S Yee
    Urology Service, Department of Surgery, Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 108:502-7. 2011
    ..Study Type - Prognosis (case series)...
  11. doi Prognostic impact of subclassification of radical prostatectomy positive margins by linear extent and Gleason grade
    Kazuma Udo
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 189:1302-7. 2013
    ..We evaluated the relationship of progression to positive surgical margin linear length and Gleason grade at a positive surgical margin...
  12. pmc Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively
    M Frank O'Brien
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 128:2373-81. 2011
    ..Although evidence that certain PSAV definitions help to predict PCSM in the cohort exist, the value of incorporating PSAV in predictive models to assist in determining eligibility for conservative management is, at best, uncertain...
  13. pmc Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  14. pmc The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer
    Brett S Carver
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 75:1431-5. 2010
    ..After the multidisciplinary management of metastatic germ cell tumor, approximately 10%-15% of patients with the histologic finding of fibrosis or teratoma will suffer disease recurrence...
  15. pmc Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer
    Jennifer M Taylor
    Department of Urology and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 109:855-9. 2012
    ..To evaluate the performance of the Isbarn nomogram for predicting 90-day mortality following radical cystectomy in a contemporary series...
  16. doi Critical evaluation of perioperative complications in laparoscopic partial nephrectomy
    Lucas Nogueira
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Urology 75:288-94. 2010
    ..Complications from LPN result from a variety of factors, both technical and inherent...
  17. pmc Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10021, USA
    J Clin Oncol 28:1112-6. 2010
    ..Clinicians who believe that it is unnecessary to prevent all cancers, but that preventing those readily detectable by screening would be desirable, would be best off recommending finasteride only to a high-risk subgroup...
  18. pmc Low annual caseloads of United States surgeons conducting radical prostatectomy
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 182:2677-9. 2009
    ..Moreover it has been shown that a surgeon needs to conduct at least 250 radical prostatectomies to maximize cancer control (the surgical learning curve)...
  19. pmc Validation study of a web-based assessment of functional recovery after radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Health Outcomes Group Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Health Qual Life Outcomes 8:82. 2010
    ..Logistical problems associated with using paper questionnaire limit their use in the clinic. We have implemented a web-interface ("STAR") for patient-reported outcomes after radical prostatectomy...
  20. pmc The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 10:475-80. 2009
    ..Here we aim to characterise the learning curve for laparoscopic radical prostatectomy...
  21. pmc Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI
    Lucas Nogueira
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urology 75:472-7. 2010
    ....
  22. doi Intraoperative conversion from partial to radical nephrectomy at a single institution from 2003 to 2008
    David J Galvin
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 185:1204-9. 2011
    ..Little information exists on conversion from partial to radical nephrectomy. We assessed the intraoperative reasons and predictive factors for conversion in a contemporary series of patients undergoing partial nephrectomy...
  23. pmc Empirical study of data sharing by authors publishing in PLoS journals
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS ONE 4:e7078. 2009
    ..These policies are explicit, but remain largely untested. We sought to determine how well authors comply with such policies by requesting data from authors who had published in one of two journals with clear data sharing policies...
  24. doi An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder
    Ryan K Berglund
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 180:1297-300; discussion 1300. 2008
    ..Some data have suggested that patients taking a statin while on bacillus Calmette-Guerin therapy experience reduced clinical efficacy...